MedTrace Logo

Access to Genetic Information Leveraging Innovative Technology (AGILITY)

NCT05159011 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-11-19

No results posted yet for this study

Summary

AGILITY is a type 1 hybrid trial that will test the effectiveness of a chatbot to provide pre-test information about genetic screening for tier 1 conditions. A randomized control trial of 2400 adult participants from diverse primary care clinics at the University of Florida Gainesville to receive virtual information about tier 1 condition genetic testing from a chatbot or traditional genetic counseling. The assessment of the outcome of the trial is to determine whether the chatbot is inferior to genetic counseling. Non-inferiority will be determined based on informed choice to undergo testing (or not). Implementation outcomes of acceptability, feasibility, and appropriateness will be evaluated to inform future potential through interviews with patients, primary care providers and GCs.

Conditions

  • Genetic Testing

Interventions

BEHAVIORAL

AGILITY (Access to Genetic Information Leveraging Innovative TechnologY)

information about genetic testing through technology

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • RTI International

    lead OTHER

Principal Investigators

  • Barbara Biesecker, PhD · RTI International

  • Alexander S Parker, PhD · University of Florida

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-31
Primary Completion
2024-09-30
Completion
2025-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05159011 on ClinicalTrials.gov